Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...